Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2809–2832 of 21,059 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Diabetes Mellitus, Type 2, Obesity
Interventions: canagliflozin, Placebo (for canagliflozin); Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 20 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sickle Cell Disease
Interventions: Alemtuzumab, Cyclophosphamide, Mycophenolate mofetil, Sirolimus, Fludarabine, Total body irradiation, Hematopoietic stem cell transplant; Drug · Radiation · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 19 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Ovarian Cancer, Uterine Cancer
Interventions: fosaprepitant, aprepitant, Oral Placebo, IV placebo; Drug · Other
Lead sponsor: Gynecologic Oncology Associates; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Epilepsy, Migraines
Interventions: intravenous topiramate; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Spinal Cord Injuries
Interventions: Hypoxia via Hypoxico Hyp-123, Sham via Hypoxico Hyp-123; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Autism Spectrum Disorder
Interventions: OT4ASD; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 4 Years to 12 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Carcinoma, Hepatocellular
Interventions: Microwave Ablation (MWA), Stereotactic Body Radiation Therapy (SBRT); Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hypertension
Interventions: Positive Affect/Self-Affirmation/Motivational Interviewing, Educational and Behavioral; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Oral Mucositis
Interventions: RRx-001, Cisplatin for injection, Radiation Therapy; Drug · Radiation
Lead sponsor: EpicentRx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 12
States / cities: Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: NT0102, Placebo; Drug
Lead sponsor: Neos Therapeutics, Inc; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada + 1 more

Conditions: Advanced Solid Tumor
Interventions: Hyperpolarized 13C-Pyruvate, Magnetic Resonance Imaging (MRI), 13C,15N-Urea; Drug · Procedure
Lead sponsor: Robert Bok, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stroke, Shoulder Pain
Interventions: Peripheral Nerve Stimulation; Device
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 21 Years to 89 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Krabbe Disease
Interventions: FBX-101; Biological
Lead sponsor: Duke University; Other
Eligibility: Up to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Treatment-Resistant Hypertension
Interventions: Structured center-based lifestyle intervention, Standard education and physician advice; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 35 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Renal Transplant Osteodystrophy
Interventions: Risedronate, Placebo; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Respiratory Syncytial Virus Infection
Interventions: Abrysvo, Beyfortus; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 8
States / cities: Atlanta, Georgia • Baltimore, Maryland • New York, New York + 5 more

Conditions: Smoking, Smoking Cessation, Adherence, Nicotine Dependence, Motivation
Interventions: Short Term Combination Nicotine Replacement Therapy (patch + gum), Long Term Combination Nicotine Replacement Therapy (patch + gum), Intensive Maintenance Counseling, Cognitive Medication Adherence Counseling (CAM), Electronic Medication Monitoring Device (the Helping Hand) + Feedback, Automated Adherence Prompting Phone Calls; Drug · Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 99 Years
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Brain and Central Nervous System Tumors
Interventions: GDC-0084, radiation therapy; Drug · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 21 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Autism Spectrum Disorder
Interventions: Social Value Learning Training; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 15 Months to 21 Months
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: West Nile Virus
Interventions: WN/DEN4Δ30 Vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 50 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Baltimore, Maryland • Burlington, Vermont

Conditions: Child Development
Interventions: Not listed
Lead sponsor: Mathematica Policy Research, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Biliary Cancer
Interventions: SPI-1620, Docetaxel; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: Miami, Florida • Tampa, Florida • St Louis, Missouri + 3 more

Conditions: Lung Cancer
Interventions: low-dose helical computed tomography, chest radiography; Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 55 Years to 74 Years
Enrollment: 53,454 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2010
U.S. locations: 33
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 29 more

Conditions: Weight Loss, Gestational Diabetes Mellitus in Pregnancy, Postpartum Care
Interventions: Metformin Hcl 850Mg Tab, Lifestyle Intervention, Enhanced Lifestyle Intervention; Drug · Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Pharmacokinetics and Safety of Intravenous Topiramate in Adult Patients

Intermittent Hypoxia to Enhance Motor Function After Spinal Cord Injury

Telehealth Intervention for Autism Spectrum Disorder

Randomized Trial Comparing Stereotactic Body Radiation Therapy to Microwave Ablation for the Treatment of Localized Hepatocellular Carcinoma

Trial Using Motivational Interviewing Positive Affect and Self-Affirmation in Hypertension (TRIUMPH)

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

Peripheral Nerve Stimulation for Shoulder Pain: Dose Response

Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT

Lifestyle Interventions in Treatment-Resistant Hypertension

Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.

The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products

Evaluation of Treatments to Improve Smoking Cessation Medication Adherence

Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas

Social Value Training in Toddlers With Elevated Autism Symptoms

Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age

Home-Based Child Care Toolkit for Nurturing School-Age Children Study

Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

National Lung Screening Trial (NLST) Screening

Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes